Garuda was founded and is supported by experts in blood stem cell and bone marrow transplants as well as leaders with expertise in bringing transformative medicines to patients.
Former Principal Faculty,
Harvard Stem Cell Institute
Former Associate Member,
Broad Institute of MIT and Harvard
Co-Director,
Harvard Stem Cell Institute
Gerald and Darlene Jordan
Professor of Medicine, Harvard University
Investigator,
Howard Hughes Medical Institute
Director, Children’s Research Institute,
UT Southwestern Medical Center
Founder, President, and CEO
Garuda Therapeutics, Inc.
Partner
Aisling Capital
Managing Partner
OrbiMed
Director
Northpond Ventures
Co-Founder and CEO
National Resilience, Inc.
CEO
Decibel Therapeutics
Managing Director at Cormorant Asset Management
Co-Director, Harvard Stem Cell Institute
Gerald and Darlene Jordan Professor of Medicine, Harvard University
Investigator, Howard Hughes Medical Institute
Founder & Director, Children’s Research Institute at UT Southwestern Medical Center
Professor of Medicine, Stanford University
Former Chief of the Division of Blood and Marrow Transplantation, Stanford University
Executive Director, Connell and O’Reilly Families Cell Manipulation Core Facility, Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Head, Division of Hematologic Malignancies &
Alan N. Houghton Chair, Memorial Sloan Kettering Cancer Center
Professor of Hematology-Oncology, University of Pennsylvania School of Medicine
Assistant Professor of Pediatrics, Stanford University School of Medicine
Distinguished McKnight Professor of Pediatrics, University of Minnesota
Harvard Medical School
May
24
2023
Partnership has potential to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies
MINNEAPOLIS, May 24, 2023 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced a working partnership with Garuda Therapeutics, a company working to create off-the-shelf, durable blood stem cell-based cellular therapies. read more →
February
8
2023
One cell therapy to treat them all – or at least 120-plus different diseases. Garuda Therapeutics closed a $62 million Series B round Tuesday to support its off-the-shelf, self-renewing blood stem cell technology.
Using a patient’s own depleted cells or seeking out a biological donor match is both costly and time prohibitive. Garuda’s proprietary hematopoietic stem cells could be the industry’s first off-the-shelf offering, leading to faster, more effective treatments and greater patient accessibility. read more →
February
7
2023
The science that led Garuda Therapeutics Inc. to a $62 million series B financing was a combination of hard work, luck and serendipity, according to co-founder and CEO Dhvanit Shah.
At the Harvard Stem Cell Institute, Shah and his fellow researchers found that endothelial cells go through significant modifications before becoming hematopoietic stem cells. That simple discovery, as Shah told BioWorld, brought on research leading to the possibility that patients would not need a marrow donor before receiving a stem cell treatment. read more →
February
7
2023
Fifteen months after launching with $72 million and a mission to treat 70 different diseases with stem cell-based drugs, Garuda Therapeutics has raised another $62 million and now says it’s looking at 120 potential target diseases.
Garuda announced the new funding on Tuesday morning. Backing the Series B round are lead investors Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management and Aisling Capital, with participation from Sectoral Asset Management, Mass General Brigham Ventures, Alexandria Venture Investments and others. read more →
February
7
2023
Garuda Therapeutics brought in $62 million via a Series B to take its off-the-shelf cell therapies into the clinic next year.
The Boston-area biotech wants to rid the need for blood stem cell transplants and instead give patients self-renewing blood stem cells. The proceeds, which add to a $72 million Series A from September 2021, will bankroll two lead programs in hematological and oncology indications, Garuda said Tuesday morning. read more →
February
7
2023
January
5
2023
November
15
2022
September
7
2022
March
15
2022
January
6
2022
January
5
2022
November
8
2021
September
23
2021
September
23
2021
September
23
2021
September
23
2021
We are seeking team members who share our passion for science, work ethic, and sense of urgency to improve patients’ lives.